hVIVO PLC (LSE:HVO) - Overview

Stock Report

hVIVO PLC HVO

Last Price
GBX172.00

Day Change
0.00|0.00%

As of 30/11/2016
10:41:37 GMT | GBX
Minimum 15 Minutes Delay.

Last Close172.00p
Day Range167.25 - 177.00
Mkt Cap134.30Mil
52-Wk Range166.75 - 235.57
Yield %0.00
ISINGB00B6ZM0X53
Volume580
P/E-7.01
P/S15.37
P/CF-12.55

Share Price

Total Returns 05/12/2016

 Chg (%)  
More ...
hVIVO PLC0.29 
FTSE 100 TR GBP1.22
 
Financials
201320142015
More ...
Income Statement
Turnover27.4918.477.72
Operating Profit-1.41-23.05-22.00
Net Profit1.51-18.44-17.91
Reported EPS2.90-31.30-26.00
Balance Sheet
Current Assets47.2061.2763.06
Non Current Assets4.758.2121.69
Total Assets51.9569.4884.74
Current Liabilities8.364.6217.50
Total Liabilities9.098.3021.12
Total Equity42.8661.1863.62
Cash Flow
Operating Cash Flow-3.53-19.15-13.60
Net Change in Cash-3.089.52-8.63
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2016-17.50-17.10--10.06---
2017-17.30-16.80--10.24---
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
17/10/2016PurchaseMr Jaime Ellertson180.108,54615,391.00
17/10/2016PurchaseMr. Jim Winschel180.102,2214,000.00
09/08/2016PurchaseMr Jaime Ellertson186.507,80114,549.00
09/08/2016PurchaseMr. Jim Winschel186.502,1454,000.00

Company Profile

hVIVO PLC is a life science company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases.
 

Sector

Biotechnology

Market Position

800 of 1864 Companies

Index

Outlook

(22/09/2016) ceo - "...platform is well-positioned to run at its full potential, positioning hVIVO to advance game-changing therapies with ever-growing speed and agility in 2017 and beyond"

Next Event 31/12/2016

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-10.2313.5916.10
Div Yld (E)0.004.234.35
PEG (E)0.000.550.19
ROCE-33.26209.79-30.25
Op Mrgn-270.35-15.64-33.57
EPS Grwth0.008.6822.86
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr Jaime Ellertson
Chief Executive OfficerKym Denny
Chief Financial & Business Officer & CSGraham Yeatman
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.